Supplemental Figure S1. Phenotypical analysis of DCs generated from mouse bone marrow. Bone marrow cells were cultured for 6 days in the presence of GMCSF and IL-4 (10 ng/ml each). $CD11c^+$ cells were isolated using magnetic cell sorting and flow cytometry analysis for the expression of the indicated specific markers was performed. The DC culture did not contain any conventional cytotoxic immune cells such as $CD49b^+$ (NK), $F4/80^+$ (macrophages), $CD3^+$ (T lymphocytes) or $B220^+$ (B lymphocytes) cells.

Supplemental Figure S2. Th-1 lymphocytes generated from C57BL/6 mice are capable of inducing the tumoricidal activity of C57BL/6 bone marrow-derived DCs. Day 6 $CD11c^+$ DCs were cultured for 48 hours with the supernatant of Th-1 lymphocytes. DCs were then washed extensively and incubated for 48 hours with tumor cells. KDCs activated with LPS (1 μg/ml) ([DC] LPS) were used as positive controls. Tumor cell survival was then determined. Mean +/- SD from triplicate cultures. (*$p < 0.001$).

Supplemental Figure S3. Th-1 KDC express MHC Class I-SIINFEKL complexes after co-culture with B16-OVA tumor cells. $CD11c^+$ DCs were treated with LPS ([DC] LPS), IFN-γ ([DC] IFN-γ) or Th-1 supernatant ([DC] Th-1), and cultured with B16-OVA melanoma cells as indicated in Figure 7A. DCs were then selected from the culture using CD11c microbeads and stained with anti-H-2Kb-SIINFEKL and anti-CD11c antibodies and analyzed by flow cytometry. Data are representative of 2 independent experiments.

Supplemental Figure S4. A. Analysis of DCs isolated from the tumor draining lymph nodes of DT-treated CD11c-DTR mice injected with Th-1 KDCs. Mice bearing palpable B16-OVA tumors were treated with diphtheria toxin on 2 consecutive days. Th-1 activated KDCs were then injected into the tumors and $CD11c^+$ cells were isolated from the tumor draining lymph nodes after 36 hours. Cells were then stained with anti-CD11c Ab and analyzed by flow cytometry to assess the purity of the cells and to confirm the absence of contamination with endogenous (GFP^+) DCs. Representative dot plots of two independent experiments are shown. **B. Th-1 KDC injected into B16-OVA tumors are capable of activating OVA-specific OT-II lymphocytes.** DCs obtained from the experiments described in Figure 7B were cultured with lymphocytes isolated from OT-II mice and the proliferation of the cells was evaluated using BrdU incorporation assays as described in material and methods. *, a significant difference when compared to OT-II lymphocytes cultured with untreated DC ($p<0.05$).